1. HBW Insight

ADHD Supplement Firm Turns Attention To Ingredient Supply After NAD Review

 
• By Eileen Francis

Vaya marketed Vayarin supplement in the US, but its parent firm, specialty chemicals company Enzymotec, responds to NAD request for substantiation by saying that it changed "its strategy to focus on serving as an ingredient-supplier rather than engaging in the sale of consumer products." Change includes closing Vaya and ceasing Vayarin sales in the US.

Closed sign

Enzymotec Ltd.not only pulled a product marketed by its Vaya Pharma Inc. US subsidiary but exited product marketing altogether after the National Advertising Division asked about ADHD symptom claims for its Vayarin dietary supplement.

Vaya was the exclusive US manufacturer and supplier of Vayarin, a proprietary lipid-based composition targeting management of attention deficit-hyperactivity disorder developed by its Enzymotec,and Israeli

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation